All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
• Hepatera Ltd., of Moscow, a biotech company that is part of Maxwell Biotech Venture Fund's portfolio, said it enrolled the first three patients with chronic hepatitis B virus (HBV) in its Phase Ib/IIa study of Myrcludex B, a drug designed to inhibit the essential HBV receptor on the liver cell surface, preventing the infection of healthy cells and viral spreading in the liver. Results are expected by the end of 2013.